Topotecan HCl

製品コードS1231 別名:NSC609699, Nogitecan HCl, SKFS 104864A

Topotecan HCl化学構造

分子量(MW):457.91

Topotecan HClは一種のトポイソメラーゼI阻害剤ですが、無細胞試験でMCF-7 Luc細胞とDU-145 Luc細胞に作用する時のIC50値が13nMと2nMにそれぞれ分かれます。

サイズ 価格 在庫  
USD 289 あり
USD 226 あり
USD 403 あり

カスタマーフィードバック(2)

  • Cells were treated at the same concentrations as in Caspase3/7 assay for 16 hours and total cell lysates were prepared for Western blotting. GAPDH was used as a loading control.

    BMC Cancer, 2015, 10.1186/s12885-015-1231-z. Topotecan HCl purchased from Selleck.

    Pax3:Foxo1a knockdown increases select chemotherapy sensitivities. MTS assay was performed for Pax3:Foxo1a knockdown mouse aRMS tumor cells treated with DNA damaging agents and microtubule inhibitors. Pax3:Foxo1a knockdown reduced the concentration at which viability was impaired by 50% (IC50) of topotecan by 4.8 fold, respectively, yet did not affect the IC50 of mafosfamide.

    PLoS Genet 2014 10(1), e1004107. Topotecan HCl purchased from Selleck.

製品安全説明書

Topoisomerase阻害剤の選択性比較

生物活性

製品説明 Topotecan HClは一種のトポイソメラーゼI阻害剤ですが、無細胞試験でMCF-7 Luc細胞とDU-145 Luc細胞に作用する時のIC50値が13nMと2nMにそれぞれ分かれます。
特性 Topotecan is a water-soluble derivative of camptothecin.
ターゲット
Topo I (DU-145 Luc cells) [1]
(Cell-free assay)
Topo I (MCF-7 Luc cells) [1]
(Cell-free assay)
2 nM 13 nM
体外試験

Stronger drug activity of Topotecan is observed for DU-145 Luc and MCF-7 Luc cells. [1] Topotecan causes cytotoxicity during the course of DNA replication by stabilizing the covalent complex between topoisomerase I and DNA and preventing the religation of enzyme-linked single-strand DNA break. Topotecan stabilizes topoisomerase I/DNA cleavable complexes in radiation-resistant human B-lineage acute lymphoblastic leukemia (ALL) cells, causes rapid apoptotic cell death despite high-level expression of bcl-2 protein, and inhibits ALL cell clonogenic growth in a dose-dependent fashion. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human MDA-MB-435 cells MWDDfZRwfG:6aXRCpIF{e2G7 M2\XO|czKGh? M1e2NGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj20N|Uh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygbYM2OD1zIH7N M17nXVIxOzdzMUiz
human Bel7402 cells MYfDfZRwfG:6aXRCpIF{e2G7 NGPiTYw6PiCq MUDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDC[Yw4PDB{IHPlcIx{KGGodHXyJFk3KGi{czDifUBOXFRiYYPzZZktKEmFNUC9NU4zKG6P NGL6cYgyPTF4NUG0OC=>
human HCT8 cells MX7DfZRwfG:6aXRCpIF{e2G7 NULZPYRCQTZiaB?= Mkn1R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNVQCClZXzsd{Bi\nSncjC5OkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUGuOUBvVQ>? NFrlZlkyPTF4NUG0OC=>
human MCF7 cells NEP3ZWtEgXSxdH;4bYPDqGG|c3H5 MkS1PVYhcA>? MUTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MT64JI5O NVTZRlM{OTVzNkWxOFQ>
human A549 cells NV32OJBCS3m2b4TvfIlkyqCjc4PhfS=> MVG5OkBp M4nIbmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[W[2ZYKgPVYhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2zMlIhdk1? M{HWWVE2OTZ3MUS0
human colon carcinoma SW620 cell M{\PTWN6fG:2b4jpZ:Kh[XO|YYm= NWPHWmdrS3m2b4TvfIlkKHCxdHXueIlifGmxbjDv[kBVd3CxdHXjZY4hMFSSKTDifUB1cGViY3;tdI92dmRiaX6gbJVu[W5iY3;sc44h[2G{Y3nuc41iKFOZNkKwJINmdGxibHnu[UwhUUN3ME2zMlIhdk1? MnTrNVI1ODh5MEe=
human MESSA cells M3GxXWN6fG:2b4jpZ:Kh[XO|YYm= NHe2TGQ4OiCq MUTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSXNUSSClZXzsd{Bi\nSncjC3NkBpenNiYomgZYxidWG{IHLseYUh[XO|YYmsJGlEPTB;NDDuUS=> NILYUVUzOTN2MU[3OC=>
human BGC823 cells M3i1cGN6fG:2b4jpZ:Kh[XO|YYm= MYO5OkBp MWHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDCS2M5OjNiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME20MlMhdk1? MlvRNVUyPjVzNES=
human Ketr3 cells MmTYR5l1d3SxeHnjxsBie3OjeR?= MUG5OkBp MVrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDL[ZRzOyClZXzsd{Bi\nSncjC5OkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUSuPUBvVQ>? M3fFSFE2OTZ3MUS0
LOX cells NIjDVY9EgXSxdH;4bYPDqGG|c3H5 NFPVSIZEgXSxdH;4bYNqfHlid3HzJIRmfGW{bXnu[YQhcW5idnn0do8hcW5iTF;YJINmdGy|IDjt[Yxidm:vYTmgc4YhcHWvYX6geJVud3JiY3XscEBtcW6nczDifUB2e2mwZzDNWHQh[XO|YYmsJGlEPTB;NTDuUS=> NUPsdWtXPzh3M{OzNS=>
human A549 cells MlX5SpVv[3Srb36gZZN{[Xl? MYe0JIg> M3n2[GFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZYZ1\XJiNDDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTVibl2= NVXTXJdCOTh{MEe3OFg>
human H69 cells MWTDfZRwfG:6aXRCpIF{e2G7 NYH3[YxUPzJiaB?= NUnQXlltS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUDZ7IHPlcIx{KGGodHXyJFczKGi{czDifUBidGGvYYKgZox2\SCjc4PhfUwhUUN3ME22JI5O MkXxNlE{PDF4N{S=
human A2780 cells MX7DfZRwfG:6aXRCpIF{e2G7 MorOO|IhcA>? NIC4empEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCOjd6MDDj[YxteyCxdnXy[ZhxemW|c3nu[{BidHCqYUXi[ZRiOyCrboTl[5JqdiCjc4Pld5Nm\CCjczDj[YxtKHO3co\peoFtKGGodHXyJFczKGi{czDifUBUWkJiYYPzZZktKEmFNUC9OkBvVQ>? NGLBeGszOjl3OUK0Oi=>
human LNCAP cells MV;DfZRwfG:6aXRCpIF{e2G7 M4rZ[lczKGh? M3r5[mN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGxPS0GSIHPlcIx{KGGodHXyJFczKGi{czDifUBidGGvYYKgZox2\SCjc4PhfUwhUUN3ME25JI5O NWnHVVJSOjF|NEG2O|Q>
human HOP62 cells NH7LcXFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MV\Hdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDIU3A3OiClZXzsd{BjgSCoaY\lMYRwe2ViZ4Lve5RpKGmwaHnibZRqd25iYYPzZZktKEmFNUC9NVAhdk1? M13MblI2QTB7Mke5
human MCF7 cells MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkLoS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUWNHPyClZXzsd{BjgSCoaY\lMYRwe2ViZ4Lve5RpKGmwaHnibZRqd25iYYPzZZktKEmFNUC9NVAhdk1? MmTDNlU6ODl{N{m=
human UACC62 cells NG\CNI1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGTNUXRIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBWSUOFNkKgZ4VtdHNiYomg[ol3\S2mb4PlJIdzd3e2aDDpcohq[mm2aX;uJIF{e2G7LDDJR|UxRTFyIH7N NV\kUI9ROjV7MEmyO|k>
human DU145 cells M1K0dWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4XIXWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGRWOTR3IHPlcIx{KGK7IH\peoUu\G:|ZTDndo94fGhiaX7obYJqfGmxbjDhd5NigSxiSVO1NF0yOCCwTR?= MUiyOVkxQTJ5OR?=
LoVo cell line NY\FRnRkS3m2b4TvfIlkyqCjc4PhfS=> M{PHXmN6fG:2b4jpZ{Bxd3SnboTpZZRqd25ib3[gWI9xd3SnY3HuJEhVWCliYomgeIhmKGOxbYDveY5lKGmwIDjoeY1idiClb3zvdoVkfGGuIHPhcoNmeiCOb2\vJINmdGxibHnu[UwhUUN3ME2xNU43KG6P NFHqU4wyOjRyOEewOy=>
human lymphoblast tumor cell line RPM18402 MUTDfZRwfG:6aXRCpIF{e2G7 M4XKcWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJIx6dXCqb3LsZZN1KHS3bX;yJINmdGxibHnu[UBTWE1zOESwNkwhUUN3ME2xNkBvVQ>? M1rFOFEzOzl{N{S1
human HL60 cells MnS2SpVv[3Srb36gZZN{[Xl? M2naU2FvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjMOlAh[2WubIOgZpkhW1KEIH3leIhw\CxiSVO1NF0yOiCwTR?= NWr2Wm9EOTl3NEG0PFM>
human A375 cells Mm\ER5l1d3SxeHnjxsBie3OjeR?= MmHDO|IhcA>? NVrTb3VnS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTN5NTDj[YxteyCjZoTldkA4OiCqcoOgZpkh[WyjbXHyJIJtfWViYYPzZZktKEmFNUC9NVMhdk1? MlOzNlE{PDF4N{S=
COR-L23/P cell MlTnR5l1d3SxeHnjxsBie3OjeR?= MnrIR5l1d3SxeHnjbZR6KG2nYYP1doVlKHW|aX7nJJRp\SCFT2KtUFI{KHCjcnXueIFtKCiFT2KtUFI{N1BrIHj1cYFvKG6xbjDzcYFtdCClZXzsJIx2dmdiY3HyZ4lvd22jIHPlcIwhdGmwZTygTWM2OD1zMz6yJI5O MXGxNVgxPjd{NB?=
human NCI-H460 cells MoToVJJwdGmoZYLheIlwdiCjc4PhfS=> MkDhO|IhcA>? Ml;2RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCQQ1mtTFQ3OCClZXzsd{Bi\nSncjC3NkBpenNiYomgZ492dHSncjDjc5VvfGW{IHHuZYx6e2m|LDDJR|UxRTF4IH7N NWT2SIJFOjF5OEOzOlk>
human MOLT4 cells Mo\jR5l1d3SxeHnjxsBie3OjeR?= NYDGSINnPzJiaB?= NF7qZlhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOV0yWNDDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVE6KG6P NI\RcY0zPDlyMEeyOS=>
human LoVo cells NGLQ[HdEgXSxdH;4bYPDqGG|c3H5 MWe3NkBp NYjFdVRvS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVG:YbzDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVIxKG6P MXWyNFM4OTF6Mx?=
RPM18402 tumor cell line MlOwVJJwdGmoZYLheIlwdiCjc4PhfS=> NIfNOXlEd26lZX70doF1cW:wIILldZVqemWmIITvJIlvcGmkaYSgZ4VtdCCycn;sbYZmemG2aX;uJIlvKFKSTUG4OFAzKHS3bX;yJINmdGxibHnu[UwhUUN3ME2yNEBvVQ>? NHjobnQyPTR6MkmyPS=>
human SN12C cells M4XLVmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXvoWWd{T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hW05zMlOgZ4VtdHNiYomg[ol3\S2mb4PlJIdzd3e2aDDpcohq[mm2aX;uJIF{e2G7LDDHTVUxRTJyIH7N NVLGcJBZOjV7MEmyO|k>
human RPMI8226 cells NEfxSJhEgXSxdH;4bYPDqGG|c3H5 M1vkfmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHJRVUl6MkK2JINmdGy|IHL5JG1VXCCvZYToc4QtKEmFNUC9NlEhdk1? NVPnUpE4OTlyMUK5PVY>
HT-29 cells MlrIR5l1d3SxeHnjxsBie3OjeR?= MWrDfZRwfG:6aXPpeJkhf2G|IHTleIVzdWmwZXSgbY4hfmm2cn:gbY4hUFRvMkmgZ4VtdHNqY3;sc44qKG:oIHj1cYFvKHS3bX;yJINmdGxibHnu[ZMh[nlidYPpcochVVSWIHHzd4F6NCCLQ{WwQVI2KG6P M2HKcVc5PTN|M{G=
SK-BR-3 cells MUXDfZRwfG:6aXRCpIF{e2G7 NWnWPJBUUW5iVnn0do8h[3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4h[nKnYYP0JINidmOncjDj[YxtKGyrbnWgLHNMNUKULUOpMEBKSzVyPUK2JI5O NEH4W4YyOTN|NEW2PS=>
HeLa cells MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmHvS5Jwf3SqIHnubIljcXSrb36gc4YhUGWOYTDj[YxteyCjZoTldkA1KGSjeYOsJGdKPTB;M{Cgcm0> NH3mUHgyPzRzOEW4Ni=>
UACC 62 cells NVXFbGFkS3m2b4TvfIlkyqCjc4PhfS=> Mki2WIV{fGWmIHnuJJZqfHKxIH\vdkBkgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckB1fW2xcjDj[YxtKGyrbnWgWWFESyB4MjCocYVt[W6xbXGpMEBIUTVyPUOwJI5O M3fwS|ExPzF2NUCy
human HCT116 cells NHHaWG1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1jsXGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhEXDFzNjDj[YxteyCkeTDmbZZmNWSxc3Wg[5Jwf3SqIHnubIljcXSrb36gZZN{[XluIFfJOVA:OzBibl2= MWKyOVkxQTJ5OR?=
human lung cancer cell line (H128) Ml;iR5l1d3SxeHnjxsBie3OjeR?= MnzYTY4hXmm2cn:gZ5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gcJVv\yClYX7j[ZIh[2WubDDsbY5mKCiKMUK4LUwhUUN3ME2zNUBvVQ>? M1zFPVEyOzN2NU[5
human MES-SA/Dx5 cells NFP5T4pEgXSxdH;4bYPDqGG|c3H5 MmrzR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWVUNVODL1T4OUBk\WyuczDveoVz\XiycnXzd4lv\yCPRGKxJIFnfGW{IEeyJIhzeyCkeTDhcIFu[XJiYnz1[UBie3OjeTygTWM2OD1|MzDuUS=> NV3TeGMyOjF|NEG2O|Q>
human A2780 cells MVLDfZRwfG:6aXRCpIF{e2G7 NUXrR5RtPzJiaB?= MXXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBNlc5OCClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUOzJI5O NVTJUmM{OjR7MEC3NlU>
human MDA-MB-435 cells NGXjbnJEgXSxdH;4bYPDqGG|c3H5 M2\oe|czKGh? MnzDR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUSzOUBk\WyuczDpcoN2[mG2ZXSg[o9zKDd{IHjyd{BjgSCPVGSgZZN{[XluIFfJOVA:OzRibl2= NH\nTVczOjh4N{CxPS=>
human stomach cancer cell line (MKN45) NXfFR246S3m2b4TvfIlkyqCjc4PhfS=> NXXnXXBVUW5iVnn0do8h[3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4he3SxbXHjbEBk[W6lZYKgZ4VtdCCuaX7lJEhOU052NTmsJGlEPTB;M{igcm0> MUCxNVM{PDV4OR?=
human KB3-1 cells Mlv3R5l1d3SxeHnjxsBie3OjeR?= MoPjR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT2I{NTFiY3XscJMh[W[2ZYKgUXRVKGG|c3H5MEBKSzVyPUSwJI5O M3r0VFE5QDJ7M{O0
mouse P388 cells NXjT[VNZS3m2b4TvfIlkyqCjc4PhfS=> MWjDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDQN|g5KGOnbHzzJIFnfGW{IF3UWEBie3OjeTygTWM2OD12NTDuUS=> MX2xPFgzQTN|NB?=
A427 human lung carcinoma MnPJVJJwdGmoZYLheIlwdiCjc4PhfS=> NHnPVphCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBu\WG|dYLl[EBi\2GrboP0JGE1OjdiaIXtZY4hdHWwZzDjZZJkcW6xbXGsJGlEPTB;NEmgcm0> MmXnPVg4PjFzMR?=
human U251 cells M4TmWmZ2dmO2aX;uJIF{e2G7 MVO2MVI1KGh? NHzzS4RKdmirYnn0bY9vKG:oIITvdI9qe2:vZYLhd4UuOSCrbjDoeY1idiCXMkWxJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiaInwc5hq[S2rbnT1Z4VlKEiLRj2xZYxxcGFiYXPjeY12dGG2aX;uJIlvKG63Y3zlZZIh\Xi2cnHjeEBi\nSncjC2JJRwKDJ2IHjyd{BjgSCrbX31co9jdG:2IHHuZYx6e2m|LDDFR|UxRTV2IH7N M1ew[FIzOzB3NkGy
human colon cancer cell line (WiDr) MVzDfZRwfG:6aXRCpIF{e2G7 MnLXTY4hXmm2cn:gZ5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gZ49td25iY3HuZ4VzKGOnbHygcIlv\SBqV3nEdkktKEmFNUC9OVYhdk1? M1zvWFEyOzN2NU[5
human HepG2 cells M4\vXGN6fG:2b4jpZ:Kh[XO|YYm= NHPkNJU1KGSjeYO= M2DhXWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmeEd{IHPlcIx{KGGodHXyJFQh\GG7czDifUBOXFRiYYPzZZktKEmFNUC9OlAhdk1? NVHEVIxjOTh3NUS5NFY>
human KB cells NVWye3ZuS3m2b4TvfIlkyqCjc4PhfS=> Mn3hO|IhcA>? NEDhW|BEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBMSiClZXzsd{Bi\nSncjC3NkBpenNic4Xs[o9zcG:mYX3pcoUhSiClb3zvdolu\XS{aXOgZZN{[XluIFnDOVA:PjJwNTDuUS=> NX60[GZ1OjVyMEi0OVY>
human HCT8 cells NG\heZJEgXSxdH;4bYPDqGG|c3H5 NWCweGtnOyCmYYnz NFrKc|REgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS1R6IHPlcIx{KGGodHXyJFMh\GG7czDifUBOXFRiYYPzZZktKEmFNUC9O|Ahdk1? M3ToTVIxOzl{NUS1
human GBM2 cells NFLhdI5Rem:uaX\ldoF1cW:wIHHzd4F6 NIPpbZI4OiCq NU[x[|NCSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDHRm0zKGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCrbnP1ZoF1\WRiZn;yJFczKGi{czDifUBYW1RvMTDt[ZRpd2RuIFnDOVA:OC5zMzFOwG0> NFPHbXQzPjN3NUWzNi=>
SK-MEL-2 cells NEXoVZdEgXSxdH;4bYPDqGG|c3H5 MXy3NkBp M3HQTmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNMNU2HTD2yJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCjbHHtZZIh[my3ZTDhd5NigSxiSVO1NF0xNjF2IN88US=> NXWwS4czOjF|NEG2O|Q>
human IGROV1 cells MUPDfZRwfG:6aXRCpIF{e2G7 NHjH[mE4OiCq MYjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDJS3JQXjFiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JIFt[W2jcjDicJVmKGG|c3H5MEBKSzVyPUCuNVYh|ryP MWSyNVM1OTZ5NB?=
human U87 cells NUDWfWp2WHKxbHnm[ZJifGmxbjDhd5NigQ>? M1jYVlQ5KGh? NF\EOGlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGW4O{Bk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNVYh|ryP MXOyOFgzPjhzOB?=
human HT1080 cells NYDOd|Z4WHKxbHnm[ZJifGmxbjDhd5NigQ>? NWPlOlBxPDhiaB?= M4ThPWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSGSxNFgxKGOnbHzzJIF{e2W|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGmwY4XiZZRm\CCob4KgOFghcHK|IHL5JJN2dG[xcnjv[IFucW6nIFKgZZN{[XluIFnDOVA:OC5zODFOwG0> MVWyOlQxQDhzNR?=
human Hep3B cells NW\4cY1xWHKxbHnm[ZJifGmxbjDhd5NigQ>? NGO4TGk4OiCq MXHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEincEPCJINmdGy|IHHmeIVzKDd{IHjyd{BjgSC[VGSgZZN{[XluIFfJOVA:OC5{MjFOwG0> NFzZUIsyQTd7Nkm1Oi=>
human GBM3 cells MVPQdo9tcW[ncnH0bY9vKGG|c3H5 NEfIbY04OiCq MkDLRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCJQl2zJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fUBqdmO3YnH0[YQh\m:{IEeyJIhzeyCkeTDXV3QuOSCvZYToc4QtKEmFNUC9NE4{QCEQvF2= M3XQc|I3OzV3NUOy
human KBVIN cells NVXLbJZXS3m2b4TvfIlkyqCjc4PhfS=> MlLvO|IhcA>? NUPOfJhbS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hU0KYSV6gZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KFOUQjDhd5NigSxiSVO1NF0xNjRizszN M3zT[FI2PDN6N{[5
human GBM1 cells MoCxVJJwdGmoZYLheIlwdiCjc4PhfS=> MkC2O|IhcA>? MYfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEeETUGgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5JIlv[3WkYYTl[EBnd3JiN{KgbJJ{KGK7IGfTWE0yKG2ndHjv[EwhUUN3ME2wMlQ3KM7:TR?= MWSyOlM2PTV|Mh?=
human U937 cells NVq4NINmS3m2b4TvfIlkyqCjc4PhfS=> NXzvOWpzPDhiaB?= NWL2c4dDS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hXTl|NzDj[YxteyCneIDy[ZN{cW6pIIC1N{BufXSjboSgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTFvwKwhUUN3ME2xMlEh|ryP MnO1NVk4OTV|MUm=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Animals inoculate s.c. with DU-145 Luc cells and then treated with Topotecan demonstrates significant tumor growth and regression as measured with calipers and luminescent imaging. The correlation coefficient is 0.75 for the control untreated group and 0.93 for the Topotecan-treated group. Similarly, tumor progression and regression are measurable using luminescent imaging for untreated and Topotecan-treated mice inoculated i.p. with MCF-7 Luc cells. [1] Topotecan elicited potent antileukemic activity in severe combined immune-deficiency (SCID) mouse models of human poor prognosis ALL. Topotecan markedly improved event-free survival of SCID mice challenged with otherwise fatal doses of humaln leukemia cells at systemic drug exposure levels. [2] Gliomas preferentially express TRAIL R2 and that treatment with Topotecan significantly up-regulates its expression. [3]

お薦めの試験操作(参考用のみ)

細胞試験:

[1]

+ 展開
  • 細胞株: MCF-7 Luc and DU-145 Luc cells
  • 濃度: 0 μg/mL - 0.692 μg/mL
  • 反応時間: 96 hours
  • 実験の流れ:

    Topotecan is dissolved in sterile water to a stock concentration of 1 mg/mL, diluted to 6 μg/mL in cultured medium and then serially diluted 1:4 in opaque, white tissue culture-treated microplates to a final volume of 0.1 mL/well. MCF-7 Luc and DU-145 Luc cells are resuspended in 3×104 cells/mL in DMEM with high glucose containing 10% FBS and 0.5 mg/mL Geneticin; 100 μL of cells are added in each well. Plates are incubated for 4 days at 37 °C in 95% humidity/5% CO2. After incubation, 0.05 mL of 0.1 M HEPES buffer (pH 7.9) containing 50 μg/mL D-luciferin is added to each well. After incubation at room temperature for 10 minutes, the culture microplate is measured in a microplate luminometer and a molecular light imager. Results obtained with the microplate luminometer are calculated using no inhibition control wells without exogenous drug and maximum inhibition control wells containing ATP inhibitor. Results for the molecular light imager are similarly calculated using values obtained with a 5 minutes luminescent imager.


    (参考用のみ)
動物試験:

[1]

+ 展開
  • 動物モデル: Mice with MCF-7 Luc or DU-145 Luc cells
  • 製剤: PBS
  • 投薬量: 0.25 mg/mL
  • 投与方法: Administered via i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 92 mg/mL (200.91 mM)
Water 92 mg/mL (200.91 mM)
Ethanol slightly soluble or insoluble
体内 順序で溶剤を入れること:
Saline
30 mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 457.91
化学式

C23H23N3O5.HCl

CAS No. 119413-54-6
保管
in solvent
別名 NSC609699, Nogitecan HCl, SKFS 104864A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00553189 Completed Solid Tumors|Lymphomas National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) August 9, 2007 Phase 1
NCT00117013 Completed Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) June 28, 2005 Phase 1
NCT02980809 Not yet recruiting Small Cell Lung Cancer First Hospitals affiliated to the China PLA General Hospital March 2017 Phase 2
NCT02963090 Not yet recruiting Small Cell Lung Cancer Alliance Foundation Trials, LLC.|Merck Sharp & Dohme Corp. December 2016 Phase 2
NCT02348398 Withdrawn Cervical Cancer M.D. Anderson Cancer Center|GlaxoSmithKline August 2016 Phase 2
NCT02822157 Not yet recruiting Ovarian Epithelial Cancer Universitaire Ziekenhuizen Leuven|AstraZeneca August 2016 Phase 2

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    I would like get the compound for mice intraperitoneally injection, What would you recommend to improve solubility? What could I use as solvent (%v?) that is nontoxic (unlike Methanol) and could be injected into mice intraperitoneally?

  • 回答:

    Topotecan HCl is generally prepared by Saline for I.P. administration.

Topoisomerase信号経路図

相関Topoisomerase製品

Tags: Topotecan HClを買う | Topotecan HCl ic50 | Topotecan HCl供給者 | Topotecan HClを購入する | Topotecan HCl費用 | Topotecan HCl生産者 | オーダーTopotecan HCl | Topotecan HCl化学構造 | Topotecan HCl分子量 | Topotecan HCl代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID